ArticleClinical epigenetics2026
Investigation of multilocus imprinting disturbance (MLID) in 101 Beckwith-Wiedemann spectrum patients.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Epigenomics in Rare Diseases: Interpreting DNA Methylation Episignatures.Molecular genetics & genomic medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Beckwith-Wiedemann spectrum (BWSp) is an overgrowth disorder caused by both genetic and epigenetic defects within the 11p15.5 chromosomal region. The most common cause of BWSp is DNA methylation anomalies in two imprinting control regions (ICR1, the telomeric centre that includes H19/IGF2:IG-DMR and ICR2, the centromeric centre that includes KCNQ1OT1:TSS-DMR) located within the 11p15.5 locus. Previous studies demonstrated that a subset of BWSp patients had methylation defects extending beyond 11p15.5 to other chromosomal loci, an entity known as multilocus imprinting disturbances (MLID). In this study, the multilocus methylation status of 101 BWSp patients was analysed by both various methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA-ME034) and methylation microarrays. MS-MLPA-ME034 detected MLID in 16 (15.8%) of the patients, which increased to 59 (58.4%) using methylation microarrays. ICR2 hypomethylation was observed in all MLID cases, and 28 imprinted differentially methylated regions (DMRs) were additionally detected. Recurrent loci associated with the genes such as GNAS, MEST, and DIRAS3, previously reported in MLID patients, were also observed as hypomethylated in our cohort. Seven out of the 48 (14.6%) MLID-BWSp patients with complete data on type of conception were born following assisted reproductive technologies (ART), indicating an appreciable proportion of MLID among ART-conceived pregnancies. This study underscores the value of genome-wide methylation analyses in revealing molecular complexity, improving diagnostic accuracy, and informing prenatal care in BWSp with MLID. Future research should further explore the long-term clinical implications of MLID and the underlying molecular mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.